{
    "clinical_study": {
        "@rank": "100944", 
        "arm_group": [
            {
                "arm_group_label": "healthy_0", 
                "description": "healthy, people with normal (negative) colonoscopy results."
            }, 
            {
                "arm_group_label": "patient_1", 
                "description": "people with biopsy/surgery verified carcinoma of the colon, either an Adenocarcinoma, or carcinoma in situ"
            }, 
            {
                "arm_group_label": "benign_2", 
                "description": "people with biopsy verified benign polyps of the colon one of the following - Villus adenoma, Tubular adenoma, Low grade dysplasia, Intermediate grade dysplasia, High grade dysplasia, Severe dysplasia"
            }
        ], 
        "biospec_descr": {
            "textblock": "Human plasma samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The OctavaColon tests are qualitative plasma tests that are indicated to people above 18\n      years of age suspected with colon abnormality. The blood tests will provide additional\n      information to the doctor in the course of colon cancer diagnosis for both normal population\n      and high risk population"
        }, 
        "brief_title": "OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Colon Cancer", 
        "condition_browse": {
            "mesh_term": "Colonic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The clinical objective of this study is to develop two antibody-based blood tests for\n      additional information during colon cancer diagnosis -\n\n        1. Highly specific (OctavaGold) - provides additional information to doctors during\n           evaluation of normal population.\n\n        2. Highly sensitive (OctavaSilver) - provides additional information to doctors during\n           evaluation of high risk population.\n\n      The study will be considered successful it can achieve at least one of the following sets of\n      performances -\n\n        1. For the OctavaGold - 95% specificity with at least 50% sensitivity.\n\n        2. For the OctavaSilver - 95% sensitivity with at least 50% specificity. The biological\n           objective of this study is to find the best set of antigens, that when combined with\n           the appropriate algorithm will support each of the above clinical objectives"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects 18 years or over. Subjects scheduled for colonoscopy or surgery\n\n        Exclusion Criteria:\n\n          -  Subjects less than 18 years of age\n\n          -  Previous or concurrent synchronous cancers other than previous malignancies of the\n             colon and recovered melanoma\n\n          -  Autoimmune disorders diagnosed subjects\n\n          -  Hematological malignancies\n\n          -  Subjects under active chemotherapy treatment or chemotherapy in the past 6 months\n\n          -  Steroid treatment in the past 3 months\n\n          -  Subject undergoing immunosuppressive treatments\n\n          -  Subject with verified melanoma colon cancer\n\n          -  Subject with verified sarcoma colon cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "There are 3 different populations that will participate in the study-\n\n          1. Any person with suspected colon abnormality, that will be classified after\n             colonoscopy/surgery as \"colon cancer patient\" will be a part of group1 - \"Patient\".\n\n          2. Any person with suspected colon abnormality, that will be classified after\n             colonoscopy as \"benign polyp\" will be a part of group2 - \"benign\".\n\n          3. Any person with suspected colon abnormality, that will be classified after\n             colonoscopy as \"normal/healthy\" will be a part of group0 - \"healthy\"."
            }
        }, 
        "enrollment": {
            "#text": "1080", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066259", 
            "org_study_id": "OctavaColon_001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "colon cancer", 
            "cancer associated auto antibodies", 
            "colon cancer blood test"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GilbertS@clalit.org.il", 
                    "last_name": "Gilbert Sabag, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Beer Sheva", 
                        "country": "Israel", 
                        "zip": "85025"
                    }, 
                    "name": "Soroka Medical Center"
                }, 
                "investigator": {
                    "last_name": "Gilbert Sabag, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bitterman@clalit.org.il", 
                    "last_name": "Arie Bitterman, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "34362"
                    }, 
                    "name": "\"Carmel\" Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Arie Bitterman, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Lilly Merdler, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Dabbah Kamal, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Adi.Lahat@sheba.health.gov.il", 
                    "last_name": "Adi Lahat, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Ramat gan", 
                        "country": "Israel", 
                        "zip": "52621"
                    }, 
                    "name": "Sheba Tel hashomer"
                }, 
                "investigator": {
                    "last_name": "Adi Lahat, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_groups": "3", 
        "official_title": "OctavaColon Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol", 
        "overall_contact": {
            "email": "galit@eventusdx.com", 
            "last_name": "Galit Yahalom, Ph.D", 
            "phone": "+972546922422"
        }, 
        "overall_official": {
            "affiliation": "Eventus Dx", 
            "last_name": "Galit Yahalom, Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants in each of the clinicaly defined groups (0,1 and 2).", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "reference": {
            "PMID": "24324350", 
            "citation": "Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM. An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis. Biomark Cancer. 2013 Nov 19;5:71-80. doi: 10.4137/BIC.S13236. eCollection 2013."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066259"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eventus Diagnostics Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eventus Diagnostics Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}